<DOC>
	<DOCNO>NCT01424982</DOCNO>
	<brief_summary>The goal clinical research study learn intensive chemotherapy combine ponatinib , follow maintenance therapy , help control ALL Ph chromosome and/or BCR-ABL . The safety treatment also study . Ponatinib may cause blood clot form artery vein . Depending location clot , could cause heart attack , stroke , severe damage tissue , death . A blood clot may occur within 2 week start take drug . About 25 % ( 1 4 ) patient take drug form abnormal clot . Blood clot occur patient know risk factor form clot . If develop blood clot , need stop take ponatinib . In case , emergency surgery could need remove clot restore blood flow .</brief_summary>
	<brief_title>Hyper-CVAD Ponatinib Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>Study Drugs : The intensive chemotherapy use study include combination 7 chemotherapy drug . These drug include cyclophosphamide , vincristine , Adriamycin ( doxorubicin ) , dexamethasone , methotrexate , cytarabine ( Ara-C ) , ponatinib . This call hyper-CVAD . You may also receive rituximab . These chemotherapy drug design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . The maintenance therapy use study include combination 3 chemotherapy drug . These drug include vincristine , prednisone , ponatinib . Cytarabine design insert DNA ( genetic material cell ) stop DNA repairing . Cyclophosphamide design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Ponatinib design block protein cancer may need grow , survive , spread . Dexamethasone , doxorubicin , methotrexate , prednisone design stop slow growth cancer cell , may cause cell die . Vincristine design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Rituximab design attach leukemia cell , may cause die . Study Drug Administration : If find eligible take part study , receive intensive chemotherapy therapy ponatinib follow maintenance therapy . You receive 2 kind intensive chemotherapy regimen ( hyper-CVAD therapy methotrexate plus cytarabine ) alternate every 3 week total 8 cycle ( 4 course regimen ) . Each study cycle 3-4 week . Intensive Chemotherapy : You may receive 8 cycle intensive chemotherapy hospital ( 4 5 day inpatient ) . For participant 60 year old , receive entire first course hospital ( 21 day ) , protect environment , healthy recovery blood count . Hyper-CVAD : Cycles 1 , 3 , 5 , 7 : On Days 1-3 Cycles 1 , 3 , 5 , 7 , receive cyclophosphamide vein 3 hour 2 time day every 12 hour . While receive cyclophosphamide , receive mesna continuous infusion central venous catheter ( CVC ) start 1 hour receive cyclophosphamide end 12 hour last dose cyclophosphamide . Mesna give low risk side effect . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . On Days 1 11 Cycles 1 , 3 , 5 , 7 ( +/- 2 day ) , receive vincristine vein 30 minute . On Day 4 Cycles 1 , 3 , 5 , 7 , receive doxorubicin CVC 24-48 hour . On Days 1-4 11-14 Cycles 1 , 3 , 5 , 7 ( +/- 2 day ) , take dexamethasone mouth 1 time day vein 30 minute . On Days 1-14 Cycle 1 every day Cycles 2-8 , take ponatinib mouth 1 time day . If doctor think need , Days 1 11 Cycles 1 3 Days 1 8 Cycles 2 4 , may also receive rituximab vein several hour . You also receive methotrexate alternate cytarabine spinal tap ( intrathecally ) help low risk disease come back fluid surround brain . A spinal tap ( also call lumbar puncture ) fluid surround spinal cord remove insert needle low back . The affected area numb local anesthetic procedure . It also use give chemotherapy . The number dose receive depend many dos study doctor think need . If start leukemia brain , give 2 time week leukemia present 1 time week 4 week . Occasionally , sample fluid obtain spinal tap may test leukemia . A sample also test see reach fluid around brain . On Day 2 Cycles 1 , 3 , 5 ( +/- 2 day ) , receive intrathecal methotrexate . On Day 7 Cycles 1 , 3 , 5 ( +/- 2 day ) , receive intrathecal cytarabine . Methotrexate alternate cytarabine vein : Cycles 2 , 4 , 6 , 8 On Day 1 Cycles 2 , 4 , 6 8 , receive methotrexate vein 24 hour ( +/- 3 hour ) . On Days 1-3 Cycles 2 , 4 , 6 , 8 , receive methylprednisolone vein le 30 minute every 12 hour . On Days 2 3 Cycles 2 , 4 , 6 , 8 , receive cytarabine vein 2 time day 3 hour time . On Days 2-5 Cycles 2 , 4 , 6 , 8 , receive leucovorin vein 1 hour mouth every 6 hour begin 12 hour ( +/- 2 hour ) finish receive methotrexate . Leucovorin give low risk side effect mouth sore kidney damage . On Day 5 Cycles 2 , 4 , 6 ( +/- 2 day ) , receive intrathecal cytarabine . On Day 8 Cycles 2 , 4 , 6 ( +/- 2 day ) , receive intrathecal methotrexate . You also receive filgrastim pegfilgrastim cycle Hyper-CVAD methotrexate plus cytarabine . You receive either injection skin every day , chemotherapy , healthy recovery white blood cell , determine study doctor . If disease respond therapy intolerable side effect , continue intensive chemotherapy 8 course , go maintenance therapy phase . You take study disease get bad intolerable side effect . Maintenance Therapy : Maintenance therapy , last 2 year , give complete 8 course intensive chemotherapy . Each maintenance cycle 28 day . On Day 1 , receive vincristine vein 30 minute . On Days 1-5 , take prednisone mouth . You take ponatinib single dose every day mouth . You may continue take ponatinib every day long receive benefit intolerable side effect . Post-Remission Therapy : During Months 6 13 , may receive another course hyper-CVAD , depend feeling status disease . Your dos chemotherapy give study may increase decreased depend organ function side effect . Throughout intensive chemotherapy maintenance therapy , also receive drug , fluid , blood product ( antibiotic , antiemetic , antacid , saline , platelet , plasma ) , include allopurinol ( mouth ) rasburicase ( vein ) , help protect body tumor lysis syndrome . This condition bring death large tumor , cause damage kidney . Study Visits : At study visit , ask feeling drug may take . Before Day 1 Cycle 2 , ECG ( +/- 2 day ) . On Day 1 Cycles 2 , 4 , 6 , 8 , chest x-ray . Blood ( 1 tablespoon ) drawn routine test 1-2 time week Cycle 1 , every 1-4 week Cycles 2-8 , every 4-8 week maintenance cycle . You bone marrow aspiration and/or biopsy ( 1 teaspoon ) check status disease Days 14 21 ( +/- 5 day ) Cycle 1 , every 2-3 cycle consolidation , every 3-6 month maintenance . Beginning Cycle 3 , ECHO MUGA scan every 3 month . The blood draws routine test , bone marrow aspirations/biopsies , ECGs may repeat often anytime doctor think need . Length Treatment : You may receive intensive chemotherapy 8 cycle ( 8 month ) maintenance therapy 2 year . You may continue take ponatinib long receiving benefit . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete follow-up . Follow-up : You follow-up visit 30 day last dose study drug . At visit , ask side effect may . If make clinic visit , do phone member study staff . The phone call last 10 minute . Long-Term Follow-Up : Every 6 month ( +/- 1 month ) long allow , study staff may call ask side effect may . These phone call last 10 minute . If already follow-up call another relate study ( follow-up study call DR09-0223 ) , call part study . This investigational study . Ponatinib FDA approve treat patient certain type leukemia . Its use study investigational . All drug use study FDA approve commercially available . Their use together study investigational . Up 100 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Diagnosis one following : ) Previously untreated Phpositive ALL [ either ( 9 ; 22 ) and/or bcrabl positive ] ( include patient initiate first course hyperCVAD cytogenetics know ) ; b ) Previously treat Phpositive ALL , 12 course chemotherapy without TKIs 1 ) If achieve CR , assessable eventfree overall survival , 2 ) If fail achieve CR , assessable CR , eventfree , overall survival . 2 . Age &gt; /= 18 year 3 . Performance status &lt; /= 2 ( ECOG Scale , Appendix E ) 4 . Adequate liver function define follow criterion : ) Total serum bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) , unless due Gilbert 's syndrome , b ) Alanine aminotransferase ( ALT ) &lt; /= 2 x ULN , c ) Aspartate aminotransferase ( AST ) &lt; /= 2.5 x ULN ) 5 . Adequate pancreatic function define follow criterion : ) Serum lipase amylase &lt; /= 1.5 x ULN ) , 6 . For female childbearing potential , negative pregnancy test must document prior randomization 7 . Female male patient fertile must agree use effective form contraception sexual partner randomization 4 month end treatment 8 . Adequate cardiac function assess clinically history physical examination . 9 . Signed informed consent 1 . Active serious infection control oral intravenous antibiotic 2 . History acute pancreatitis within 1 year study history chronic pancreatitis 3 . History alcohol abuse 4 . Uncontrolled hypertriglyceridemia ( triglyceride &gt; 450mg/dL ) 5 . Active secondary malignancy skin cancer ( e.g. , basal cell carcinoma squamous cell carcinoma ) investigator 's opinion shorten survival less 1 year 6 . Active Grade IIIV cardiac failure define New York Heart Association Criteria 7 . Clinically significant , uncontrolled , active cardiovascular disease , specifically include , restrict : Any history myocardial infarction ( MI ) , stroke , revascularization ; Unstable angina transient ischemic attack prior enrollment ; Congestive heart failure prior enrollment , leave ventricular ejection fraction ( LVEF ) less low limit normal per local institutional standard prior enrollment ; Diagnosed suspect congenital long QT syndrome ; Any history clinically significant atrial ventricular arrhythmia ( atrial fibrillation , ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) determine treat physician ; Prolonged QTc interval preentry electrocardiogram ( &gt; 470 msec ) unless correct electrolyte replacement ; Any history venous thromboembolism include deep venous thrombosis pulmonary embolism ; 8 . Continued # 7 : Uncontrolled hypertension ( diastolic blood pressure &gt; 90mmHg ; systolic &gt; 140mmHg ) . Patients hypertension treatment study entry effect blood pressure control . 9 . Patients currently take drug generally accept risk cause Torsades de Pointes ( unless change acceptable alternative ) 10 . Taking medication herbal supplement know strong inhibitor CYP3A4 within least 14 day first dose ponatinib 11 . Prior history treatment ponatinib 12 . Treatment investigational antileukemic agent chemotherapy agent last 7 day study entry , unless full recovery side effect occur patient rapidly progressive disease judge lifethreatening investigator 13 . Pregnant lactate woman eligible ; woman childbearing potential negative pregnancy test prior enter study willing practice method contraception . Women childbearing potential hysterectomy postmenopausal without menses 12 month . In addition , men enrol study understand risk sexual partner childbearing potential practice effective method birth control 14 . History significant bleeding disorder unrelated cancer , include : ) Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) , b ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) 15 . Patients document significant pleural pericardial effusion unless think secondary leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Ph-positive acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Philadelphia ( Ph ) chromosome</keyword>
	<keyword>BCR-ABL</keyword>
	<keyword>Depo-Medrol</keyword>
	<keyword>Medrol</keyword>
	<keyword>Solu-Medrol</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Ponatinib</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>NeupogenTM</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Wellcovorin</keyword>
	<keyword>Citrovorum</keyword>
	<keyword>Prednisone</keyword>
	<keyword>NeulastaTM</keyword>
	<keyword>PEG-G-CSF</keyword>
</DOC>